ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

Core Insights - ABVC BioPharma, Inc. has entered a licensing agreement with OncoX to advance treatments for Non-Small Cell Lung Cancer (NSCLC) through the development of a botanical drug extract from Maitake Mushroom [1][2][3] Company Overview - ABVC BioPharma is a clinical-stage biopharmaceutical company focused on developing therapeutic solutions in ophthalmology, CNS, and Oncology/Hematology [1][6] - The company has an active pipeline of six drugs and one medical device, utilizing in-licensed technology from renowned research institutions [6] Licensing Agreement Details - The agreement grants OncoX exclusive rights to develop, manufacture, and commercialize BLEX 404, a combination therapy drug for NSCLC [2][4] - ABVC and its affiliate will receive an aggregate license fee of $12.5 million, with an additional milestone payment of $1.25 million after OncoX's next fundraising round [1][4] - Royalties of 5% on net sales of BLEX 404, capped at $12.5 million, will also be provided after the product launch [1][4] Market Potential - The global cancer therapeutics market is projected to grow from $164 billion in 2022 to approximately $393.61 billion by 2032, at a CAGR of 9.20% [5] - The lung cancer market was valued at $29.5 billion in 2022 and is expected to grow at an 11% CAGR through 2032 [5] Clinical Development - The FDA has approved four INDs for ABVC's products, including ABV-1519 for NSCLC, which is proposed as a combination therapy with chemotherapy [2][4] - BLEX 404, containing β-glucan from Maitake mushrooms, has shown promising results in clinical studies and is expected to improve treatment outcomes for NSCLC patients [2][4][3]